1380539-06-9
1380539-06-9
Chemical Structure
Fosciclopirox
Synonym(s): CPX-POM
- CAS No.: 1380539-06-9
- Formula:C13H20NO6P
- Molecular Weight:317.27
IUPAC Name: ((6-cyclohexyl-4-methyl-2-oxopyridin-1(2H)-yl)oxy)methyl dihydrogen phosphate
InChIKey: NTKBXPWLNROYPE-UHFFFAOYSA-N
SMILES: O=C1C=C(C)C=C(C2CCCCC2)N1OCOP(O)(O)=O
Biological Activity: Fosciclopirox (CPX-POM) suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fosciclopirox | 99.66% | Fosciclopirox (CPX-POM) suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fosciclopirox (Standard) | ≥98% | Fosciclopirox (Standard) is the analytical standard of Fosciclopirox (HY-109174). This product is intended for research and analytical applications. Fosciclopirox (CPX-POM) suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox selectively delivers the active metabolite, Ciclopirox (CPX), to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Weir SJ, et al. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex. Cell Death Dis. 2021 May 31;12(6):562. [Content Brief]
- [2]. Weir SJ, Wood R, Schorno K, Brinker AE, Ramamoorthy P, Heppert K, Rajewski L, Tanol M, Ham T, McKenna MJ, McCulloch W, Dalton M, Reed GA, Jensen RA, Baltezor MJ, Anant S, Taylor JA 3rd. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159. [Content Brief]
